| 1. |
Coburn N, Cosby R, Klein L, et al. Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treat Rev, 2017, 63: 104-115.
|
| 2. |
Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Med, 2017 Dec 13. doi: 10.1002/cam4.1274. [Epub ahead of print].
|
| 3. |
Cheng X, Lu Y. A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population. Future Oncol, 2017 Dec 18. doi: 10.2217/fon-2017-0558. [Epub ahead of print].
|
| 4. |
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol, 2006, 12(3): 354-362.
|
| 5. |
李延武, 張有成. 胃癌淋巴結轉移及其組織病理特征的回顧性研究. 中國普外基礎與臨床雜志, 2017, 24(5): 572-579.
|
| 6. |
朱信強, 張明, 丁闖, 等. 不同病理類型進展期胃癌的預后因素分析. 中國普外基礎與臨床雜志, 2017, 24(5): 580-586.
|
| 7. |
Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 2006, 24(18): 2903-2909.
|
| 8. |
Kim JE, Lee DE, Lee KW, et al. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila), 2011, 4(4): 582-591.
|
| 9. |
Li Q, Ren FQ, Yang CL, et al. Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo. Asian Pac J Cancer Prev, 2015, 16(7): 3035-3042.
|
| 10. |
Samson P, Lockhart AC. Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. J Gastrointest Oncol, 2017, 8(3): 418-429.
|
| 11. |
Yang JH, Kim SC, Kim KM, et al. Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress. Eur J Pharmacol, 2016, 783: 92-102.
|
| 12. |
Li Y, Chi G, Shen B, et al. Isorhamnetin ameliorates LPS-induced inflammatory response through downregulation of NF-κB signaling. Inflammation, 2016, 39(4): 1291-1301.
|
| 13. |
Wang J, Gong HM, Zou HH, et al. Isorhamnetin prevents H2O2-induced oxidative stress in human retinal pigment epithelial cells. Mol Med Rep, 2018, 17(1): 648-652.
|
| 14. |
Hu S, Huang L, Meng L, et al. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase kinase signaling pathways. Mol Med Rep, 2015, 12(5): 6745-6751.
|
| 15. |
Ruan Y, Hu K, Chen H. Autophagy inhibition enhances isorhamnetin-induced mitochondria-dependent apoptosis in non-small cell lung cancer cells. Mol Med Rep, 2015, 12(4): 5796-5806.
|
| 16. |
Li C, Yang D, Zhao Y, et al. Inhibitory effects of isorhamnetin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Nutr Cancer, 2015, 67(7): 1191-1200.
|
